Zai Lab is an innovative biopharmaceutical company based in China and the U.S., focused on delivering transformational outcomes to patients around the world.
Joined April 2020
- Tweets 358
- Following 218
- Followers 589
- Likes 135
279 Photos and videos
Jun 9
#Breaking: China's NMPA approved our BLA for a new treatment for adults with recurrent or metastatic cervical cancer. We will leverage our experienced oncology team in China to bring this therapy to patients in need. Learn more: tinyurl.com/459b4h6y
1
2
436
May 29
This weekend, we're at #ASCO26, highlighting the ongoing trial evaluating our investigational treatment for small-cell lung cancer. Read more here: tinyurl.com/nt4nybuf
78
May 11
#Breaking: The U.S. FDA granted Fast Track designation to our experimental targeted antibody-drug conjugate for extrapulmonary neuroendocrine carcinomas. Learn more about this milestone: tinyurl.com/385hujju
2
600
May 7
Today, we shared Q1 earnings results and notable commercial updates. Read our full earnings announcement:
tinyurl.com/32e9wj7p
1
105
May 4
#NEWS: Dr. Thummalapalli speaks to @ecancer about early-phase results evaluating zoci, a novel DLL3-targeting antibody-drug conjugate, in patients with advanced neuroendocrine carcinomas who have progressed after platinum-based chemotherapy. @rohit_thum bit.ly/49qWXKF
3
8
906
Apr 18
#Breaking at #AAI2026: We're sharing positive preclinical study results from our investigational bispecific antibody in atopic dermatitis and other disease models. Learn more: tinyurl.com/4wbxvmr2
1
1
2
462
Apr 17
At #AACR26, we will present data demonstrating the progress of our #oncology pipeline, including important new data for our investigational treatment for people with small-cell lung cancer. Learn more: tinyurl.com/4cn6zmes
2
206
Apr 15
#NEWS: We announced a clinical collaboration with @Boehringer to pioneer a potential dual DLL3-targeting investigational combination for small-cell lung cancer and other neuroendocrine carcinomas.
Learn more: tinyurl.com/2vyyhy5r #SLC #Innovation #Oncology
1
1
162
Apr 1
#NEWS: Zai Lab announces global clinical trial collaboration and supply agreement with @Amgen
Learn more: lnkd.in/gBVS8nJC
1
1
176
Mar 17
#NEWS: Zai Lab will present new data on three internally developed oncology candidates at #AACR26, including zoci (DLL3 ADC), ZL‑6201 (LRRC15 ADC), and ZL‑1222 (PD‑1/IL‑12).
Learn more: tinyurl.com/398k89ek #ADC #Oncology #Immunotherapy
294
Feb 26
#NEWS: Zai Lab announces fourth quarter and full-year 2025 financial results along with recent product highlights and corporate updates.
Learn more about our pipeline progress and healthcare innovation: tinyurl.com/5753jbdd
#earnings #financialresults #oncology #ADC
1
4
533
Feb 17
Celebrating five years of partnership with @argenxglobal. Together, we’ve accelerated development, expanded patient access, and supported thousands across China—including those living with gMG and CIDP. Grateful for our teams driving impact and innovation forward. #LifeSciences
1
4
513
Jan 13
#NEWS: Zai Lab will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco today @ 3PM PT / 6PM ET. Learn more about our 2026 strategic priorities and global pipeline progress: bit.ly/3NgL81C
#JPM26 #Innovation #ADC #oncology
1
1
273
8 Dec 2025
#NEWS: Zai Lab dosed the first participant in our Global Phase 1/1b study of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis. Discover the potential of ZL-1503: bit.ly/4rFqqs5
1
1
204
11 Nov 2025
Zai Lab's President and COO Josh Smiley spoke at @FinancialTimes Global Pharma and Biotech Summit in London today on a panel discussing China's transformation into a biopharma innovation powerhouse.
#FTPharma #Innovation #Biotech #BioPharma
1
177
6 Nov 2025
#NEWS: Zai Lab announces third quarter 2025 financial results along with recent product highlights and corporate updates.
Learn more about our pipeline progress and healthcare innovation: bit.ly/47uR3rG
#earnings #financialresults #oncology #ADC #healthcare #innovation
151
24 Oct 2025
#NEWS: Zai Lab announces updated data from the global Ph1 clinical trial of zocilurtatug pelitecan (zoci)—formerly ZL-1310— today at the AACR-NCI-EORTC International Conference. Learn more about the initiation of our global Ph3 Registrational Study: bit.ly/3WUKbgS
#ADC
3
412
13 Oct 2025
#NEWS: Zai Lab will deliver an oral presentation featuring updated data from our global Phase 1 trial of zocilurtatug pelitecan (ZL-1310) at the upcoming 2025 AACR-NCI-EORTC Conference in Boston. Visit: bit.ly/4h9clxT
#ESSCLC #DLL3 #ADC #Targets25 #LungCancer
1
282
10 Oct 2025
Join us in recognizing #WorldMentalHealthDay.
At Zai Lab, we stand with the global community in raising awareness and reducing stigma around mental health.
Join the movement to advocate for mental health worldwide: bit.ly/4mDEYEL
130
25 Sep 2025
This #WorldLungDay, Zai Lab reaffirms its commitment to advancing awareness of lung health and the global impact of lung diseases, including lung cancer.
Join the global movement to protect, promote, and prioritize lung health: bit.ly/46pt1Og
97